Microglial Metabolic Reprogramming: Mechanisms, Clinical Implications, and Therapeutic Potential

Abstract

Microglial metabolic reprogramming has emerged as a pivotal process in the regulation of central nervous system (CNS) homeostasis, neuroinflammation, and neurodegenerative diseases. This review synthesizes current evidence on the mechanisms driving metabolic shifts in microglia, their clinical relevance, and the implications for diagnosis and therapy. Special focus is placed on the integration of recent advances, risk factors, and guideline-based recommendations, providing a comprehensive resource for clinicians and researchers seeking to translate foundational insights into improved patient care.

Introduction

Microglia, the resident immune cells of the CNS, are essential to both surveillance and response within the neural microenvironment. In health and disease, their function is intimately linked to metabolic state, with recent discoveries revealing that metabolic reprogramming underlies the activation, polarization, and effector functions of microglia. Understanding these metabolic dynamics is crucial for elucidating the pathogenesis of neuroinflammatory and neurodegenerative disorders and for identifying novel therapeutic targets.

Epidemiology / Disease Burden

The relevance of microglial metabolic reprogramming is underscored by its implication in a spectrum of CNS diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and acute injuries such as stroke and traumatic brain injury. With the global burden of neurodegenerative disorders rising due to population aging, dysregulated microglial metabolism is increasingly recognized as a common thread linking diverse neuropathologies. Epidemiological data indicate that the prevalence of diseases associated with microglial dysfunction is increasing, highlighting the urgency of metabolic intervention strategies.

Pathophysiology

Microglial metabolic reprogramming refers to the dynamic shift in energy production and substrate utilization, primarily between oxidative phosphorylation (OXPHOS) and glycolysis. Upon activation by pathogenic stimuli, microglia often transition from OXPHOS to aerobic glycolysis, a phenomenon reminiscent of the Warburg effect observed in cancer cells. This shift supports rapid ATP generation and biosynthetic demands but also fuels pro-inflammatory cytokine production. Conversely, anti-inflammatory or reparative microglial phenotypes tend to rely on OXPHOS and fatty acid oxidation. Mechanistically, these metabolic states are orchestrated by signaling pathways involving mTOR, AMPK, HIF-1α, and PPARs, which integrate extracellular cues and intracellular energy status to shape microglial function.

Risk Factors

Risk factors for maladaptive microglial metabolic reprogramming include genetic predispositions (e.g., TREM2, APOE variants), systemic metabolic disturbances (such as diabetes and obesity), aging, chronic stress, and recurrent CNS injuries. Environmental factors, such as exposure to neurotoxins and infections, further modulate microglial metabolism, predisposing individuals to neuroinflammatory and neurodegenerative states. Importantly, the interplay between peripheral metabolic disorders and CNS immunity is an area of active research, as systemic inflammation can prime microglia toward pathological metabolic phenotypes.

Clinical Features

Clinically, microglial metabolic reprogramming manifests indirectly through the progression and symptomatology of CNS diseases. For example, persistent neuroinflammation in Alzheimer’s disease correlates with cognitive decline, while in multiple sclerosis, microglial-driven demyelination and axonal loss are associated with motor and sensory deficits. Although direct assessment of microglial metabolism in patients remains challenging, several biomarkers (such as soluble TREM2 and cytokine profiles) and advanced neuroimaging modalities are under investigation to improve clinical correlation and monitoring.

Diagnosis

Diagnostic approaches to microglial metabolic reprogramming primarily involve indirect techniques, including positron emission tomography (PET) imaging with TSPO tracers, magnetic resonance spectroscopy (MRS) for metabolic profiling, and the assessment of cerebrospinal fluid or plasma biomarkers. Recent advances in single-cell transcriptomics and metabolomics offer unprecedented resolution in characterizing microglial states in both animal models and human tissues. Integration of these modalities into clinical workflows remains an ongoing challenge but is essential for early detection and therapeutic stratification.

Treatment & Management

Current therapeutic strategies targeting microglial metabolism are largely experimental but encompass agents that modulate metabolic pathways, such as inhibitors of glycolysis (e.g., 2-deoxyglucose), activators of AMPK, and PPAR agonists. Neuroprotective interventions, including lifestyle modifications (diet, exercise) and control of systemic metabolic diseases, may exert beneficial effects on microglial function. In clinical practice, the management of microglial-mediated disorders remains supportive and symptomatic, with disease-modifying therapies under active investigation.

Recent Advances / Emerging Therapies

Emerging therapies focus on precise targeting of microglial metabolic pathways to restore homeostasis or promote reparative phenotypes. Novel small molecules, gene-editing approaches (e.g., CRISPR-mediated modulation of metabolic enzymes), and cell-based therapies are being explored in preclinical models. Immunometabolic modulation through dietary interventions, gut microbiome manipulation, and repurposing of metabolic drugs (such as metformin) are promising avenues. Importantly, translational studies are beginning to validate these strategies in early-phase clinical trials, with the aim of attenuating neuroinflammation and halting neurodegeneration.

Guideline Recommendations

While formal clinical guidelines specific to microglial metabolic reprogramming are not yet established, expert consensus advocates for the integration of metabolic assessment in the evaluation of neuroinflammatory and neurodegenerative conditions. Multidisciplinary management, including neurologists, immunologists, and metabolic specialists, is recommended. Ongoing surveillance of emerging evidence is crucial, and enrollment in clinical trials should be considered for eligible patients to advance the field and provide access to novel therapies.

Conclusion

The study of microglial metabolic reprogramming offers transformative insights into the mechanisms underlying CNS diseases and presents new opportunities for therapeutic intervention. Bridging the gap between bench and bedside will require continued integration of molecular research, biomarker development, and clinical translation. As the field advances, targeted modulation of microglial metabolism holds promise for reshaping the landscape of neuroinflammatory and neurodegenerative disease management.